Executive Summary

Our client, a pharmaceutical company with a new therapy for heart failure, needed to find a reliable way to assess costs associated with the therapy before phase 3 data were collected. The objective was to support health technology assessment and reimbursement processes. We used an analytical approach to develop economic models that enabled our client to meet their goals.

Download

How Glympse Bio oversubscribed their Series B funding amidst the pandemic

View Now